GSK

GlaxoSmithKline’s (GSK) global HIV business ViiV Healthcare has completed the previously announced acquisition of HIV R&D assets from Bristol-Myers Squibb .

The acquisition of Bristol-Myers’ late-stage HIV R&D assets and its portfolio of preclinical and discovery stage HIV research assets follows antitrust approval by the relevant regulatory authorities in the US.

Under the deals, ViiV Healthcare bought late-stage HIV R&D assets from Bristol-Myers Squibb for $317m.

The late stage assets include fostemsavir (BMS-663068), which is an attachment inhibitor currently in Phase III development for heavily treatment experienced patients.

The second late stage asset is a maturation inhibitor (BMS-955176) that is currently in Phase IIb development for both treatment-naive and treatment experienced patients.

The deal also covers a back-up maturation inhibitor candidate (BMS-986173).

ViiV Healthcare will provide up to $518m in potential development and regulatory milestone payments for Bristol-Myers’ clinical assets, in addition to $587m for the discovery and pre-clinical programmes.

It will also pay sales-based milestone payments of up to $750m for each of the clinical assets and up to $700m for each of the discovery and pre-clinical programmes.

The purchase includes a novel biologic (BMS-986197) with a triple mechanism of action, an additional maturation inhibitor, an allosteric integrase inhibitor and a capsid inhibitor that are currently in preclinical and discovery phases of development.

ViiV Healthcare CEO Dominique Limet said: "As a result of these transactions, ViiV Healthcare now has one of the most robust HIV pipelines in the industry.

"As a result of these transactions, ViiV Healthcare now has one of the most robust HIV pipelines in the industry."

"The assets that we have acquired complement our existing portfolio and could lead to new medicines and combinations addressing a broad range of treatment and prevention needs of people living with HIV."

In a separate development, GSK is expanding its penicillin production plant in Irvine, Scotland.

The proposed expansion is expected to create nearly 55 new jobs.

This project is being backed by a £1.5m Scottish Enterprise Regional Selective Assistance (RSA) funding.


Image: GlaxoSmithKline head office, London. Photo: courtesy of Ian Wilson.